Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is

Updated on: April 08,2024 18

Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is

Updated on:April 08,2024 18

Expensive arthritis treatment no better than steroid therapy

by Hospital for Special Surgery“On average, each of the therapies resulted in clinically meaningful improvement in pain,” said Lisa Mandl, M.D., MPH, a rheumatologist at Hospital for Special Surg

Updated on: March 24,2024 10

Expensive arthritis treatment no better than steroid therapy

by Hospital for Special Surgery“On average, each of the therapies resulted in clinically meaningful improvement in pain,” said Lisa Mandl, M.D., MPH, a rheumatologist at Hospital for Special Surg

Updated on:March 24,2024 10

Moms with systemic lupus erythematosus at double the risk of having premature or growth-restricted babies, finds study

by British Medical JournalCredit: Unsplash/CC0 Public DomainMothers with the long term autoimmune disorder, systemic lupus erythematosus, or SLE for short, run more than double the risk of giving

Updated on: June 05,2024 4

Moms with systemic lupus erythematosus at double the risk of having premature or growth-restricted babies, finds study

by British Medical JournalCredit: Unsplash/CC0 Public DomainMothers with the long term autoimmune disorder, systemic lupus erythematosus, or SLE for short, run more than double the risk of giving

Updated on:June 05,2024 4

Takayasu arteritis, ulcerative colitis co-occurrence rate high

(HealthDay)—Takayasu arteritis (TAK) has a high rate of co-occurrence and genetic overlap with ulcerative colitis (UC), according to a study published in the August issue ofArthritis & Rheum

Updated on: March 24,2024 20

Takayasu arteritis, ulcerative colitis co-occurrence rate high

(HealthDay)—Takayasu arteritis (TAK) has a high rate of co-occurrence and genetic overlap with ulcerative colitis (UC), according to a study published in the August issue ofArthritis & Rheum

Updated on:March 24,2024 20

COVID-19 can cause severe inflammation in the brain

by Albert Ludwigs University of FreiburgGraphical Abstract. Credit:Immunity(2021). DOI: 10.1016/j.immuni.2021.06.002Both during and after infection with the Coronavirus SARS-CoV-2, pa

Updated on: April 10,2024 18

COVID-19 can cause severe inflammation in the brain

by Albert Ludwigs University of FreiburgGraphical Abstract. Credit:Immunity(2021). DOI: 10.1016/j.immuni.2021.06.002Both during and after infection with the Coronavirus SARS-CoV-2, pa

Updated on:April 10,2024 18

COVID-19 model reveals key role for innate immunity in controlling viral load

by American Chemical SocietyColorized scanning electron micrograph of a cell (blue) heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample. Image captured at the N

Updated on: April 10,2024 19

COVID-19 model reveals key role for innate immunity in controlling viral load

by American Chemical SocietyColorized scanning electron micrograph of a cell (blue) heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample. Image captured at the N

Updated on:April 10,2024 19

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on: June 01,2024 7

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on:June 01,2024 7

Brain activity linked to TNF inhibitor response in RA

Patients with rheumatoid arthritis who respond to tumor necrosis factor inhibitors show changes in activity in pain-related areas of the brain before clinical signs of improvement are observed, accord

Updated on: April 08,2024 14

Brain activity linked to TNF inhibitor response in RA

Patients with rheumatoid arthritis who respond to tumor necrosis factor inhibitors show changes in activity in pain-related areas of the brain before clinical signs of improvement are observed, accord

Updated on:April 08,2024 14

Macrophages produce heat from brown adipose tissue in response to cold, study reveals

by University of TsukubaGraphical abstract. Credit:Cell Reports(2024). DOI: 10.1016/j.celrep.2024.113978Researchers from University of Tsukuba have elucidated the molecular mechanism

Updated on: March 27,2024 0

Macrophages produce heat from brown adipose tissue in response to cold, study reveals

by University of TsukubaGraphical abstract. Credit:Cell Reports(2024). DOI: 10.1016/j.celrep.2024.113978Researchers from University of Tsukuba have elucidated the molecular mechanism

Updated on:March 27,2024 0

Prevalence of knee OA lower with menopausal hormone therapy

(HealthDay)—For postmenopausal women, the prevalence of knee osteoarthritis is lower with menopausal hormone therapy (MHT) use, according to a study published online Dec. 21 inMenopause.Jae Hyun

Updated on: May 26,2024 5

Prevalence of knee OA lower with menopausal hormone therapy

(HealthDay)—For postmenopausal women, the prevalence of knee osteoarthritis is lower with menopausal hormone therapy (MHT) use, according to a study published online Dec. 21 inMenopause.Jae Hyun

Updated on:May 26,2024 5

World's first CAR-T cell therapy for a child with lupus

byFriedrich–Alexander University Erlangen–NurnbergThe medical team and their patient (left to right): Dr. Tobias Krickau, Dr. Nora Naumann-Bartsch, Patientin Uresa A., Prof. Dr. Markus Metzler,

Updated on: July 09,2024 0

World's first CAR-T cell therapy for a child with lupus

byFriedrich–Alexander University Erlangen–NurnbergThe medical team and their patient (left to right): Dr. Tobias Krickau, Dr. Nora Naumann-Bartsch, Patientin Uresa A., Prof. Dr. Markus Metzler,

Updated on:July 09,2024 0

m6A mRNA modification potentiates Th17 functions to inflame autoimmunity

by Science China PressLoss of METTL3 in Th17 cells facilitated SOCS family RNA stability, inhibited IL-6/STAT3 mediated IL-17A and CCR5 expression, which in turn impeding Th17 cells differentiati

Updated on: April 16,2024 11

m6A mRNA modification potentiates Th17 functions to inflame autoimmunity

by Science China PressLoss of METTL3 in Th17 cells facilitated SOCS family RNA stability, inhibited IL-6/STAT3 mediated IL-17A and CCR5 expression, which in turn impeding Th17 cells differentiati

Updated on:April 16,2024 11